• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
KNI
Click for more information
5.88% 18.0¢

KUNIKO LIMITED

Market Cap $15.61M  ! watchlist Created with Sketch. Add to my watchlist

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
KNI
Ann: High Grade Copper-Zinc Assays from Vaga Project 		19/09/24 0 1
19/09/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  1 

See All Discussions arrow Created with Sketch.

Timeline

High Grade Copper-Zinc Assays from Vaga Project
19 Sep 08:38
 
(20min delay)
Last
18.0¢ 		Change
0.010(5.88%) 		Mkt cap ! $15.61M
Open High Low Value Volume
15.5¢ 18.0¢ 15.5¢ $5.995K 34.85K

Buyers (Bids)

No. Vol. Price($)
1 3131 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
18.0¢ 6790 2
View Market Depth
Last trade - 16.10pm 27/09/2024 (20 minute delay) ?
Last
15.5¢ 		  Change
0.010 ( 0.00 %)
Open High Low Volume
15.5¢ 15.5¢ 15.5¢ 1500
Last updated 13.25pm 27/09/2024 ?
KNI (ASX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
The market's shrugged at China's stimulus measures all year. Why is this one different? If you've been following the Chinese economy this year, you'd know that the country has been trying to stimulate all year.
Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop What HotCopper users were watching; China outshines USA's Fed cut; Oz inflation CPI tracks downwards & more!
The winners & losers on market if negative gearing were gone Removing negative gearing would likely cause a seismic shift in investor behaviour. If that advantage were taken away, more investors might start eyeing the stock market...
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.